



PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 5/18/17  
LAST REVIEW DATE: 5/17/18  
LAST CRITERIA REVISION DATE: 5/17/18  
ARCHIVE DATE:

---

## AFREZZA® (insulin human) inhalation powder

---

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

**BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.**

---

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy).

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com). **Incomplete forms or forms without the chart notes will be returned.**

---

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 5/18/17  
LAST REVIEW DATE: 5/17/18  
LAST CRITERIA REVISION DATE: 5/17/18  
ARCHIVE DATE:

---

## AFREZZA® (insulin human) inhalation powder (cont.)

---

### Criteria:

➤ **Criteria for initial therapy:** Afrezza (insulin regular, human) inhalation powder is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:

1. Individual is 18 years of age or older
2. Hemoglobin A1C is greater than 7%
3. **For a confirmed diagnosis of inadequately controlled type 1 diabetes mellitus**, individual is concurrently on a long acting insulin product or insulin pump product which will be continued
4. **For a confirmed diagnosis of inadequately controlled type 2 diabetes mellitus**, individual is concurrently on metformin and at least 1 other oral agent for diabetes mellitus
5. Medical record documentation that the individual is unable to self-inject Humalog (insulin lispro), the preferred rapid acting insulin, due to **ONE** of the following:
  - Physical impairment
  - Visual impairment
  - Lipohypertrophy
  - Needle phobia as defined by DSM-V criteria for specific phobia (see Definitions section)
6. Baseline spirometry (FEV1) is  $\geq 70\%$  of expected normal, repeat spirometry to be done annually thereafter
7. The individual does not have active lung cancer
8. The individual does not smoke or has not recently quit smoking (within the last 6 months)
9. Will not be used in the treatment of diabetic ketoacidosis
10. There are **NO** contraindications:
  - Contraindications include:
    - Use during hypoglycemia
    - Chronic lung disease such as asthma or chronic obstructive pulmonary disease
    - Hypersensitivity to regular insulin or any excipients found in Afrezza product

**Initial approval duration:** 6 months

➤ **Criteria for continuation of coverage (renewal request):** Afrezza (insulin regular, human) inhalation powder is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:

1. The individual has achieved and maintains at least 20% improvement in HgA1c from the baseline
2. The condition has not progressed or worsened while on therapy

**PHARMACY COVERAGE GUIDELINES**  
**SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE: 5/18/17**  
**LAST REVIEW DATE: 5/17/18**  
**LAST CRITERIA REVISION DATE: 5/17/18**  
**ARCHIVE DATE:**

---

## **AFREZZA® (insulin human) inhalation powder (cont.)**

---

- Worsening is defined as:
  - Hemoglobin A1c increased while on therapy
  - Repeat pulmonary function tests show a decline of 20% or more in FEV1
- 3. Individual has been adherent with the medication
- 4. The individual does not have active lung cancer
- 5. The individual does not smoke
- 6. Individual has not developed any contraindications or other exclusions to its continued use
  - Contraindications as listed in the criteria for initial therapy section
- 7. There are no significant interacting drugs

**Renewal duration:** 12 months

---

### **Description:**

Afrezza (insulin human) inhalation powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult individuals with type 1 or type 2 diabetes mellitus (DM1 or DM2). When used in the treatment of DM1, it must be used with a long acting insulin. Afrezza (insulin human) inhalation powder is not indicated for use in the treatment of diabetic ketoacidosis and it is not recommended in individuals who smoke or recently stopped smoking within the last 6 months.

Insulin lowers blood glucose levels by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.

For individuals with DM1, an insulin regimen consisting of a basal insulin with insulin administered around meals is the standard of care. For individuals with DM2, lifestyle and behavioral changes with use of metformin are considered as first line therapy. If glycemic control remains inadequately controlled, other oral agents may be added or insulin can be considered.

Afrezza (insulin human) inhalation powder is available as 4 unit, 8 unit and 12 unit single-use cartridges. The cartridges must be used with the Afrezza breath powered inhaler. The amount of Afrezza (insulin human) inhalation powder delivered to the lung will depend on individual patient factors. The inhaler is used for up to 15 days from the date of first use after which it must be discarded and replaced with a new inhaler. The package label for Afrezza (insulin human) inhalation powder states that the faster absorption from Afrezza (insulin human) inhalation powder did not result in a faster onset of activity when compared to insulin lispro.

---

---

## AFREZZA® (insulin human) inhalation powder (cont.)

---

### Definitions:

#### **Specific phobia: DSM-5 300.29 (ICD-10- F 40.23, F40.231, F40.298)**

*Based on criteria from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association, 2013)*

1. A persistent fear that is excessive or unreasonable, that occurs by the presence or anticipation of a specific object or situation (e.g., flying, heights, animals, receiving an injection, seeing blood).
2. Exposure to the feared item or situation almost always leads to an immediate anxiety response, which may take the form of a panic attack. In children, the anxiety may be expressed by crying, tantrums, freezing, or clinging.
3. The person recognizes that the fear is excessive or out of proportion to the actual threat posed. In children, this feature may be absent.
4. The phobic situation(s) is avoided or else is endured with intense anxiety or distress.
5. The avoidance, anxious anticipation, or distress during the feared situation(s) interferes significantly with the person's normal routine, work (or school) functioning, social activities, relationships, or there is marked distress about having the phobia.
6. The fear is persistent, typically lasting for at least six months.
7. The anxiety, panic attacks, or avoidance associated with the specific object or situation are not better accounted for by another mental disorder, such as Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Separation Anxiety Disorder (e.g., avoidance of school), Social Phobia, Panic Disorder, etc.

#### **Needle phobia:**

A specific phobia characterized by a deep and persistent fear of needles, resulting in symptoms of anxiety. Symptoms may also arise from anticipating the presence of the needles. An individual displaying symptoms of anxiety may be experience:

- Increased heart rate (palpitations)
- Dizziness or unsteadiness
- Nausea
- Sweating
- Shaking or trembling
- An upset stomach
- Breathlessness

Someone suffering from a specific disorder will also display avoidance behavior, meaning that they take steps to avoid having to confront the object or situation at the center of their disorder

**PHARMACY COVERAGE GUIDELINES**  
**SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE:** 5/18/17  
**LAST REVIEW DATE:** 5/17/18  
**LAST CRITERIA REVISION DATE:** 5/17/18  
**ARCHIVE DATE:**

---

## **AFREZZA® (insulin human) inhalation powder (cont.)**

---

### **Insulin products:**

#### **Rapid acting:**

Afrezza (insulin human) – inhaled  
Apidra (insulin glulisine human analog)  
Humalog (insulin lispro human analog)  
NovoLog (insulin aspart human analog)

#### **Short acting:**

Humulin R (insulin human regular)  
Novolin R (insulin human regular)

#### **Intermediate acting:**

Humulin N (insulin human isophane NPH)  
Novolin N (insulin human isophane NPH)

#### **Long acting:**

Basaglar (insulin glargine human analog)  
Lantus (insulin glargine human analog)  
Levemir (insulin detemir human analog)  
Tresiba (insulin degludec human analog)

#### **Concentrated:**

Humulin R U-500 (insulin human regular)  
Toujeo (insulin glargine human analog, U-300)

#### **Pre-mixed:**

Humalog Mix 50/50 (lispro protamine/lispro)  
Humalog Mix 75/25 (lispro protamine/lispro)  
Humulin Mix 70/30 (NPH/regular)  
Novolin Mix 70/30 (NPH/regular)  
NovoLog Mix 70/30 (aspart protamine/aspart)  
Ryzodeg 70/30 (degludec/aspart)

#### **Insulin combinations:**

Soliqua (glargine/lixisenatide)  
Xultophy (degludec/liraglutide)

---

### **Resources:**

Afrezza product information accessed 04-28-18 at DailyMed:

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29f4637b-e204-425b-b89c-7238008d8c10>

Afrezza (insulin human) inhalation powder. Package Insert. Revised by manufacturer 09-2016. Accessed 2/10/17.

Afrezza (insulin human) Risk Evaluation and Mitigation Strategy (REMS). Revised 04-2016.

---



An Independent Licensee of the Blue Cross and Blue Shield Association

Fax completed prior authorization request form to 602-864-3126 or email to [pharmacyprecert@azblue.com](mailto:pharmacyprecert@azblue.com).  
 Call 866-325-1794 to check the status of a request.  
 All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned.**  
 Pharmacy Coverage Guidelines are available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy).

# Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

**REQUIRED:** Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Member Information			
Member Name (first & last):	Date of Birth:	Gender:	BCBSAZ ID#:
Address:	City:	State:	Zip Code:

Prescribing Provider Information			
Provider Name (first & last):	Specialty:	NPI#:	DEA#:
Office Address:	City:	State:	Zip Code:
Office Contact:	Office Phone:	Office Fax:	

Dispensing Pharmacy Information		
Pharmacy Name:	Pharmacy Phone:	Pharmacy Fax:

Requested Medication Information			
Medication Name:	Strength:	Dosage Form:	
Directions for Use:	Quantity:	Refills:	Duration of Therapy/Use:

Check if requesting **brand** only     Check if requesting **generic**

Check if requesting continuation of therapy (prior authorization approved by BCBSAZ expired)

Turn-Around Time For Review	
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent. Sign here: _____	<input type="checkbox"/> Exigent (requires prescriber to include a written statement)

Clinical Information	
1. What is the diagnosis? Please specify below. ICD-10 Code: _____ Diagnosis Description: _____	
2. <input type="checkbox"/> Yes <input type="checkbox"/> No    Was this medication started on a recent hospital discharge or emergency room visit?	
3. <input type="checkbox"/> Yes <input type="checkbox"/> No    There is absence of ALL contraindications.	

4. What medication(s) has the individual tried and failed for this diagnosis? Please specify below.  
 Important note: Samples provided by the provider are not accepted as continuation of therapy or as an adequate trial and failure.

Medication Name, Strength, Frequency	Dates started and stopped or Approximate Duration	Describe response, reason for failure, or allergy

5. Are there any supporting labs or test results? Please specify below.

Date	Test	Value

# Pharmacy Prior Authorization Request Form

**6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.**  
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

**Signature affirms that information given on this form is true and accurate and reflects office notes**

Prescribing Provider's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Please note:** Some medications may require completion of a drug-specific request form.

**Incomplete forms or forms without the chart notes will be returned.**

Office notes, labs, and medical testing relevant to the request that show medical justification are required.